Crennen Lyndsey Elizabeth sold $12K of MLAB

Crennen Lyndsey Elizabeth (CAO) sold 118 shares of MESA LABORATORIES INC /CO/ (MLAB) at $101.27 on 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Crennen Lyndsey Elizabeth
Published Jun 17, 2026, 4:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 4:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MLAB
Neutral
high confidence
Mentioned
$MLAB
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MLABNeutralLow
01

Why it matters

The newest fact is the CAO’s open-market sale details (date, shares, price, and 10b5-1 status). This typically has limited fundamental impact but can marginally influence short-term sentiment.

02

Market read

Traders may note the insider sale for sentiment/positioning, but there is no new business or regulatory catalyst.

03

What to watch

The sale size is small and explicitly pre-arranged; without additional context (e.g., multiple concurrent sales, changes in guidance), the signal-to-noise is limited.

Relevance 2/10Novelty 5/10Timing: filed 2026-06-17 (covers sale dated 2026-06-16)

Background

The article is a SEC Form 4 insider transaction disclosure for Mesa Laboratories (MLAB).

Company-level read

Ticker impact

$MLABNeutralHigh confidence
Context

MLAB disclosed an officer (CAO) open-market sale of 118 shares at $101.2670 on 2026-06-16 under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan and small share count/value, providing no new operating or regulatory catalyst.

Market effects

No sector-level read-through; this is company-specific insider liquidity activity.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as confidence erosion, especially if paired with other negative signals not present here.

Key entities

  • MLAB

    Mesa Laboratories Inc /CO/; subject of the insider sale disclosure.

  • Crennen Lyndsey Elizabeth

    CAO who sold 118 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MLABMedAI 8/10

Mesa Laboratories Inc (MLAB) Q2 2027 Earnings Call Highlights: Margin Expansion

Mesa Laboratories (MLAB) reported Q2 2027 earnings, highlighting margin expansion and strategic shifts. CEO Siddhartha Kadia discussed clinical genomics restructuring, aiming for profitability with a focus on pharmacogenomics and oncology. SDC grew 14.6% organically, while BPD saw an 8.2% decline due to timing issues. The company announced a $9.3 million savings plan, with $4.3 million reinvested. Full-year guidance is $250M-$255M revenue and $66M-$68M adjusted EBITDA.

$MLABMed

Mesa Labs (MLAB) Q2 2027 Earnings Call Transcript

Mesa Labs (MLAB) reported Q2 2027 earnings, highlighting 2.6% organic revenue growth, with Sterilization and Disinfection Control (SDC) up 14.6% and Calibration Solutions up 3.5%. Biopharmaceutical Development saw an 8.2% decline due to timing issues. The company announced cost-cutting measures in Clinical Genomics, reduced net leverage to 1.75x, and provided full-year guidance with revenues expected to grow 5-8%. A $40M share repurchase program was authorized.

$MLABHigh

Mesa Labs Revenue Rises 2.6%; Issues FY2027 Guidance

Mesa Labs reported Q2 FY2027 revenue of $62.3M, up 2.6% YoY, with net income of $4.3M. Adjusted EBITDA rose 21.1% to $17.3M. The company issued FY2027 guidance, expecting revenue of $250M-$255M and adjusted EBITDA of $66M-$68M. Mesa also announced a $40M share repurchase program.

$MLABHighAI 8/10

Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance

MESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance Lakewood, Colorado , November 9, 2026 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of critical quality